Molecular pathogenesis of acute myeloid leukemia:
A diverse disease with new perspectives

doi:10.1007/s11684-010-0220-5

Front. Med.

2010, Vol. 4

Issue (4) : 356-362 https://doi.org/10.1007/s11684-010-0220-5

Research articles

Molecular pathogenesis of acute myeloid leukemia: A diverse disease with new perspectives

Felicitas THOL¹,Arnold GANSER¹, ²,

1.Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover 30625, Germany; 2.2011-02-21 9:44:35;

Download: PDF(133 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract Acute myeloid leukemia (AML) is a very heterogeneous neoplasm of the hematopoietic stem cell. Despite important achievements in the treatment of AML, the long term survival of patients with the disease remains poor. Understanding the pathogenesis of AML better is crucial for finding new treatment approaches. During AML development hematopoietic precursor cells undergo clonal transformation in a multistep process through acquisition of chromosomal rearrangements and/or different gene mutations. Over recent years, novel gene mutations have been found in patients with AML. These mutations can be divided into two important categories, class I mutations that confer a proliferation advantage and class II mutations that inhibit myeloid differentiation. Screening for some of these mutations is now part of the initial diagnostic work-up in newly diagnosed AML patients. Information about the mutation status of specific genes is useful for risk-stratification, minimal residual disease (MRD) monitoring and increasingly also for targeted therapy, especially for patients with cytogenetically normal AML (CN-AML). Besides chromosomal rearrangements and gene mutations, epigenetic regulation of genes – meaning changes in gene expression by mechanisms other than changes in the underlying DNA sequence – also represents an important mechanism of leukemogenesis. This article reviews some of the most common mutations in CN-AML and gives a perspective of the translation of these discoveries from bench to bedside.

Keywords acute myeloid leukemia mutations risk stratification

Issue Date: 05 December 2010

Cite this article:

Felicitas THOL,Arnold GANSER,管理员. Molecular pathogenesis of acute myeloid leukemia: A diverse disease with new perspectives[J]. Front. Med., 2010, 4(4): 356-362.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-010-0220-5
https://academic.hep.com.cn/fmd/EN/Y2010/V4/I4/356

	Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin, 2002, 52(1): 23–47 PMID: 11814064
	Rowley J D, Golomb H M, Dougherty C. 15/17 translocation, a consistent chromosomalchange in acute promyelocytic leukaemia. Lancet, 1977, 1(8010): 549–550 PMID: 65649
	Breems D A, Van Putten W L, De Greef G E, Van Zelderen-Bhola S L, Gerssen-Schoorl K B, Mellink C H, Nieuwint A, Jotterand M, Hagemeijer A, Beverloo H B, L?wenberg B. Monosomal karyotype in acute myeloid leukemia: a better indicatorof poor prognosis than a complex karyotype. J Clin Oncol, 2008, 26(29): 4791–4797 PMID: 18695255
	Medeiros B C, Othus M, Fang M, Roulston D, Appelbaum F R. Prognostic impact of monosomalkaryotype in young adult and elderly acute myeloid leukemia: the SouthwestOncology Group (SWOG) experience. Blood, 2010, 116(13): 2224–2228 PMID: 20562328
	Byrd J C, Mrózek K, Dodge R K, Carroll A J, Edwards C G, Arthur D C, Pettenati M J, Patil S R, Rao K W, Watson M S, Koduru P R, Moore J O, Stone R M, Mayer R J, Feldman E J, Davey F R, Schiffer C A, Larson R A, Bloomfield C D, 0. Pretreatment cytogeneticabnormalities are predictive of induction success, cumulative incidenceof relapse, and overall survival in adult patients with de novo acutemyeloid leukemia: results from Cancer and Leukemia Group B (CALGB8461). Blood, 2002, 100(13): 4325–4336 PMID: 12393746
	Dash A, Gilliland D G. Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol, 2001, 14(1): 49–64 PMID: 11355923
	Mardis E R, Ding L, Dooling D J, Larson D E, McLellan M D, Chen K, Koboldt D C, Fulton R S, Delehaunty K D, McGrath S D, Fulton L A, Locke D P, Magrini V J, Abbott R M, Vickery T L, Reed J S, Robinson J S, Wylie T, Smith S M, Carmichael L, Eldred J M, Harris C C, Walker J, Peck J B, Du F, Dukes A F, Sanderson G E, Brummett A M, Clark E, McMichael J F, Meyer R J, Schindler J K, Pohl C S, Wallis J W, Shi X, Lin L, Schmidt H, Tang Y, Haipek C, Wiechert M E, Ivy J V, Kalicki J, Elliott G, Ries R E, Payton J E, Westervelt P, Tomasson M H, Watson M A, Baty J, Heath S, Shannon W D, Nagarajan R, Link D C, Walter M J, Graubert T A, DiPersio J F, Wilson R K, Ley T J. Recurring mutations found by sequencingan acute myeloid leukemia genome. N Engl J Med, 2009, 361(11): 1058–1066 PMID: 19657110
	Chen J, Odenike O, Rowley J D. Leukaemogenesis: more thanmutant genes. Nat Rev Cancer, 2010, 10(1): 23–36 PMID: 20029422
	Figueroa M E, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos P J, Schifano E, Booth J, van Putten W, Skrabanek L, Campagne F, Mazumdar M, Greally J M, Valk P J, L?wenberg B, Delwel R, Melnick A. DNA methylation signatures identify biologically distinctsubtypes in acute myeloid leukemia. Cancer Cell, 2010, 17(1): 13–27 PMID: 20060365
	American Associationfor Cancer Research Human Epigenome Task Force; European Union, Networkof Excellence, Scientific Advisory Board. Moving AHEAD with an international human epigenome project. Nature, 2008, 454(7205): 711–715 PMID: 18685699
	Li Z, Lu J, Sun M, Mi S, Zhang H, Luo R T, Chen P, Wang Y, Yan M, Qian Z, Neilly M B, Jin J, Zhang Y, Bohlander S K, Zhang D E, Larson R A, Le Beau M M, Thirman M J, Golub T R, Rowley J D, Chen J. Distinct microRNA expression profilesin acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A, 2008, 105(40): 15535–15540 PMID: 18832181
	Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T. Prognostic significance ofFLT3 internal tandem duplication and tyrosine kinase domain mutationsfor acute myeloid leukemia: a meta-analysis. Leukemia, 2005, 19(8): 1345–1349 PMID: 15959528
	Mead A J, Linch D C, Hills R K, Wheatley K, Burnett A K, Gale R E. FLT3 tyrosine kinase domain mutations are biologicallydistinct from and have a significantly more favorable prognosis thanFLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood, 2007, 110(4): 1262–1270 PMID: 17456725
	Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer, 2004, 4(5): 394–400 PMID: 15122210
	Pabst T, Mueller B U, Zhang P, Radomska H S, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen D G. Dominant-negative mutationsof CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha),in acute myeloid leukemia. Nat Genet, 2001, 27(3): 263–270 PMID: 11242107
	Pabst T, Eyholzer M, Fos J, Mueller B U. Heterogeneity within AML with CEBPA mutations; only CEBPAdouble mutations, but not single CEBPA mutations are associated withfavourable prognosis. Br J Cancer, 2009, 100(8): 1343–1346 PMID: 19277035
	Wouters B J, L?wenberg B, Erpelinck-Verschueren C A, van Putten W L, Valk P J, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acutemyeloid leukemia with a distinctive gene expression profile that isuniquely associated with a favorable outcome. Blood, 2009, 113(13): 3088–3091 PMID: 19171880
	Borer R A, Lehner C F, Eppenberger H M, Nigg E A. Major nucleolar proteins shuttle between nucleus andcytoplasm. Cell, 1989, 56(3): 379–390 PMID: 2914325
	Falini B, Bolli N, Liso A, Martelli M P, Mannucci R, Pileri S, Nicoletti I. Altered nucleophosmin transport in acute myeloid leukaemia with mutatedNPM1: molecular basis and clinical implications. Leukemia, 2009, 23(10): 1731–1743 PMID: 19516275
	Schlenk R F, D?hner K, Krauter J, Fr?hling S, Corbacioglu A, Bullinger L, Habdank M, Sp?th D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, D?hner H, 0. Mutations and treatment outcome in cytogenetically normal acute myeloidleukemia. N Engl J Med, 2008, 358(18): 1909–1918 PMID: 18450602
	Chou W C, Hou H A, Chen C Y, Tang J L, Yao M, Tsay W, Ko B S, Wu S J, Huang S Y, Hsu S C, Chen Y C, Huang Y N, Chang Y C, Lee F Y, Liu M C, Liu C W, Tseng M H, Huang C F, Tien H F. Distinct clinical and biologic characteristics in adult acute myeloidleukemia bearing the isocitrate dehydrogenase 1 mutation. Blood, 2010, 115(14): 2749–2754 PMID: 20097881
	Wagner K, Damm F, G?hring G, G?rlich K, Heuser M, Sch?fer I, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A A, Fiedler W, Kirchner H H, Brugger W, Zucknick M, Schlegelberger B, Heil G, Ganser A, Krauter J. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphismin cytogenetically normal acute myeloid leukemia: SNP rs11554137 isan adverse prognostic factor. J Clin Oncol, 2010, 28(14): 2356–2364 PMID: 20368538
	Paschka P, Schlenk R F, Gaidzik V I, Habdank M, Kr?nke J, Bullinger L, Sp?th D, Kayser S, Zucknick M, G?tze K, Horst H A, Germing U, D?hner H, D?hner K. IDH1 and IDH2 mutations arefrequent genetic alterations in acute myeloid leukemia and conferadverse prognosis in cytogenetically normal acute myeloid leukemiawith NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol, 2010, 28(22): 3636–3643 PMID: 20567020
	Thol F, Damm F, Wagner K, G?hring G, Schlegelberger B, Hoelzer D, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Heil G, Heuser M, Krauter J, Ganser A. Prognostic impact of IDH2mutations in cytogenetically normal acute myeloid leukemia. Blood, 2010, 116(4): 614–616 PMID: 20421455
	Chou W C, Hou H A, Chen C Y, Tang J L, Yao M, Tsay W, Ko B S, Wu S J, Huang S Y, Hsu S C, Chen Y C, Huang Y N, Chang Y C, Lee F Y, Liu M C, Liu C W, Tseng M H, Huang C F, Tien H F. Distinct clinical and biologic characteristics in adult acute myeloidleukemia bearing the isocitrate dehydrogenase 1 mutation. Blood, 2010, 115(14): 2749–2754 PMID: 20097881
	Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, Bordessoule D, Pautas C, de Revel T, Quesnel B, Huchette P, Philippe N, Geffroy S, Terre C, Thomas X, Castaigne S, Dombret H, Preudhomme C. Prognostic impact of isocitrate dehydrogenase enzymeisoforms 1 and 2 mutations in acute myeloid leukemia: a study by theAcute Leukemia French Association group. J Clin Oncol, 2010, 28(23): 3717–3723 PMID: 20625116
	Marcucci G, Maharry K, Wu Y Z, Radmacher M D, Mrózek K, Margeson D, Holland K B, Whitman S P, Becker H, Schwind S, Metzeler K H, Powell B L, Carter T H, Kolitz J E, Wetzler M, Carroll A J, Baer M R, Caligiuri M A, Larson R A, Bloomfield C D. IDH1 and IDH2 gene mutationsidentify novel molecular subsets within de novo cytogenetically normalacute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol, 2010, 28(14): 2348–2355 PMID: 20368543
	Ho P A, Alonzo T A, Kopecky K J, Miller K L, Kuhn J, Zeng R, Gerbing R B, Raimondi S C, Hirsch B A, Oehler V, Hurwitz C A, Franklin J L, Gamis A S, Petersdorf S H, Anderson J E, Reaman G H, Baker L H, Willman C L, Bernstein I D, Radich J P, Appelbaum F R, Stirewalt D L, Meshinchi S. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia, 2010, 24(5): 909–913 PMID: 20376086
	Beaupre D M, Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol, 1999, 17(3): 1071–1079 PMID: 10071302
	Ritter M, Kim T D, Lisske P, Thiede C, Schaich M, Neubauer A. Prognostic significance of N-RAS and K-RAS mutationsin 232 patients with acute myeloid leukemia. Haematologica, 2004, 89(11): 1397–1399 PMID: 15531466
	Radich J P, Kopecky K J, Willman C L, Weick J, Head D, Appelbaum F, Collins S J. N-ras mutations in adult de novo acute myelogenous leukemia: prevalenceand clinical significance. Blood, 1990, 76(4): 801–807 PMID: 2200539
	Ernst P, Wang J, Korsmeyer S J. The role of MLL in hematopoiesisand leukemia. Curr Opin Hematol, 2002, 9(4): 282–287 PMID: 12042701
	Schnittger S, Kinkelin U, Schoch C, Heinecke A, Haase D, Haferlach T, Büchner T, W?rmann B, Hiddemann W, Griesinger F. Screening for MLL tandem duplication in 387 unselected patients withAML identify a prognostically unfavorable subset of AML. Leukemia, 2000, 14(5): 796–804 PMID: 10803509
	Whitman S P, Ruppert A S, Marcucci G, Mrózek K, Paschka P, Langer C, Baldus C D, Wen J, Vukosavljevic T, Powell B L, Carroll A J, Kolitz J E, Larson R A, Caligiuri M A, Bloomfield C D. Long-term disease-free survivorswith cytogenetically normal acute myeloid leukemia and MLL partialtandem duplication: a Cancer and Leukemia Group B study. Blood, 2007, 109(12): 5164–5167 PMID: 17341662
	Yang L, Han Y, Suarez Saiz F, Saurez Saiz F, Minden M D. A tumor suppressor and oncogene: the WT1 story. Leukemia, 2007, 21(5): 868–876 PMID: 17361230
	Paschka P, Marcucci G, Ruppert A S, Whitman S P, Mrózek K, Maharry K, Langer C, Baldus C D, Zhao W, Powell B L, Baer M R, Carroll A J, Caligiuri M A, Kolitz J E, Larson R A, Bloomfield C D. Wilms' tumor 1 gene mutations independently predict poor outcomein adults with cytogenetically normal acute myeloid leukemia: a cancerand leukemia group B study. J Clin Oncol, 2008, 26(28): 4595–4602 PMID: 18559874
	Gaidzik V I, Schlenk R F, Moschny S, Becker A, Bullinger L, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, D?hner H, D?hner K, 0. Prognostic impact of WT1 mutations in cytogenetically normal acutemyeloid leukemia: a study of the German-Austrian AML Study Group. Blood, 2009, 113(19): 4505–4511 PMID: 19221039
	Damm F, Heuser M, Morgan M, Yun H, Grosshennig A, G?hring G, Schlegelberger B, D?hner K, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, D?hner H, Heil G, Ganser A, Krauter J. Single nucleotide polymorphism in themutational hotspot of WT1 predicts a favorable outcome in patientswith cytogenetically normal acute myeloid leukemia. J Clin Oncol, 2010, 28(4): 578–585 PMID: 20038731
	Becker H, Marcucci G, Maharry K, Radmacher M D, Mrózek K, Margeson D, Whitman S P, Paschka P, Holland K B, Schwind S, Wu Y Z, Powell B L, Carter T H, Kolitz J E, Wetzler M, Carroll A J, Baer M R, Moore J O, Caligiuri M A, Larson R A, Bloomfield C D. Mutations of the Wilms tumor 1 gene (WT1) in older patientswith primary cytogenetically normal acute myeloid leukemia: a Cancerand Leukemia Group B study. Blood, 2010, 116(5): 788–792 PMID: 20442368
	Marcucci G, Maharry K, Radmacher M D, Mrózek K, Vukosavljevic T, Paschka P, Whitman S P, Langer C, Baldus C D, Liu C G, Ruppert A S, Powell B L, Carroll A J, Caligiuri M A, Kolitz J E, Larson R A, Bloomfield C D. Prognostic significance of,and gene and microRNA expression signatures associated with, CEBPAmutations in cytogenetically normal acute myeloid leukemia with high-riskmolecular features: a Cancer and Leukemia Group B Study. J Clin Oncol, 2008, 26(31): 5078–5087 PMID: 18809607
	Green C L, Koo K K, Hills R K, Burnett A K, Linch D C, Gale R E. Prognostic significance of CEBPA mutations in a largecohort of younger adult patients with acute myeloid leukemia: impactof double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol, 2010, 28(16): 2739–2747 PMID: 20439648
	Schnittger S, Kohl T M, Haferlach T, Kern W, Hiddemann W, Spiekermann K, Schoch C. KIT-D816 mutationsin AML1-ETO-positive AML are associated with impaired event-free andoverall survival. Blood, 2006, 107(5): 1791–1799 PMID: 16254134
	Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, Raffoux E, Leblanc T, Thomas X, Hermine O, Quesnel B, Baruchel A, Leverger G, Dombret H, Preudhomme C, 0, 0. Incidence and prognostic impact of c-Kit, FLT3,and Ras gene mutations in core binding factor acute myeloid leukemia(CBF-AML). Leukemia, 2006, 20(6): 965–970 PMID: 16598313
	Neubauer A, Maharry K, Mrózek K, Thiede C, Marcucci G, Paschka P, Mayer R J, Larson R A, Liu E T, Bloomfield C D. Patients with acute myeloid leukemia and RAS mutations benefit mostfrom postremission high-dose cytarabine: a Cancer and Leukemia GroupB study. J Clin Oncol, 2008, 26(28): 4603–4609 PMID: 18559876
	Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J, Allen C, Green C, Quentmeier H, Drexler H, Burnett A, Linch D, Bonnet D, Lister T A, Fitzgibbon J. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapyresistance in normal karyotype acute myeloid leukemia: the UnitedKingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol, 2008, 26(33): 5429–5435 PMID: 18591546
	Papadaki C, Dufour A, Seibl M, Schneider S, Bohlander S K, Zellmeier E, Mellert G, Hiddemann W, Spiekermann K. Monitoring minimal residual disease in acute myeloidleukaemia with NPM1 mutations by quantitative PCR: clonal evolutionis a limiting factor. Br J Haematol, 2009, 144(4): 517–523 PMID: 19055671
	Bacher U, Badbaran A, Fehse B, Zabelina T, Zander A R, Kr?ger N. Quantitative monitoring ofNPM1 mutations provides a valid minimal residual disease parameterfollowing allogeneic stem cell transplantation. Exp Hematol, 2009, 37(1): 135–142 PMID: 19100523
	Krauter J, Hoellge W, Wattjes M P, Nagel S, Heidenreich O, Bunjes D, Ganser A, Heil G. Detection and quantification of CBFB/MYH11 fusion transcripts in patients withinv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. Genes Chromosomes Cancer, 2001, 30(4): 342–348 PMID: 11241787

[1]	Shengfen Wang, Yang Zhou, Bing Zhao, Xichao Ou, Hui Xia, Yang Zheng, Yuanyuan Song, Qian Cheng, Xinyang Wang, Yanlin Zhao. Characteristics of compensatory mutations in the rpoC gene and their association with compensated transmission of Mycobacterium tuberculosis[J]. Front. Med., 2020, 14(1): 51-59.
[2]	Xiaoxin Wu, Lanlan Xiao, Lanjuan Li. Research progress on human infection with avian influenza H7N9[J]. Front. Med., 2020, 14(1): 8-20.
[3]	Meng Lv, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang, Xiaodong Mo. Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia[J]. Front. Med., 2019, 13(6): 667-679.
[4]	Xiaoxiao Chen, Yanjing Tang, Jing Chen, Ru Chen, Longjun Gu, Huiliang Xue, Ci Pan, Jingyan Tang, Shuhong Shen. Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia[J]. Front. Med., 2019, 13(3): 378-387.
[5]	Liru Qiu, Fengjie Yang, Yonghua He, Huiqing Yuan, Jianhua Zhou. Clinical characterization and diagnosis of cystic fibrosis through exome sequencing in Chinese infants with Bartter-syndrome-like hypokalemia alkalosis[J]. Front. Med., 2018, 12(5): 550-558.
[6]	Zhan Su, Fengyu Wu, Weiyu Hu, Xiaodan Liu, Shaoling Wu, Xianqi Feng, Zhongguang Cui, Jie Yang, Zhenguang Wang, Hongzai Guan, Hongguo Zhao, Wei Wang, Chunting Zhao, Jun Peng. Philadelphia chromosome-positive acute myeloid leukemia with masses and osteolytic lesions: finding of 18F-FDG PET/CT[J]. Front. Med., 2017, 11(3): 440-444.
[7]	Yuting Tan,Han Liu,Saijuan Chen. Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse[J]. Front. Med., 2015, 9(4): 412-420.
[8]	Du Yan, Han Xue, Pu Rui, Xie Jiaxin, Zhang Yuwei, Cao Guangwen. Association of miRNA-122-binding site polymorphism at the interleukin-1 α gene and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk[J]. Front. Med., 2014, 8(2): 217-226.
[9]	Chunquan Cai, Ouyan Shi. Genetic evidence in planar cell polarity signaling pathway in human neural tube defects[J]. Front Med, 2014, 8(1): 68-78.
[10]	Zhe Zheng, Lu Zhang, Xi Li, Shengshou Hu, on behalf of the Chinese CABG Registry Study. SinoSCORE: a logistically derived additive prediction model for post-coronary artery bypass grafting in-hospital mortality in a Chinese population[J]. Front Med, 2013, 7(4): 477-485.

Viewed

Full text

Abstract

Cited

Shared

Discussed